

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4256324

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
SEQUENCE:	1
CONVEYING PARTY DATA	
Name	Execution Date
MAURICE RAYMOND VERSCHOYLE FINLAY	06/17/2015
JON JAMES WINTER-HOLT	06/17/2015
JOHANNES WILHELMUS MARIA NISSINK	06/17/2015
PIOTR ANTONI RAUBO	06/17/2015
RECEIVING PARTY DATA	
Name:	ASTRAZENECA UK LIMITED
Street Address:	2 KINGDOM STREET
City:	LONDON
State/Country:	ENGLAND
Postal Code:	W2 6BD
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15314562
CORRESPONDENCE DATA	
Fax Number:	(301)576-6932
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	301-398-3199
Email:	IPdocketing@MedImmune.com
Correspondent Name:	MEDIMMUNE, INC.
Address Line 1:	ONE MEDIMMUNE WAY
Address Line 4:	GAITHERSBURG, MARYLAND 20878
ATTORNEY DOCKET NUMBER:	200230-US-PCT
NAME OF SUBMITTER:	DENISE COOPER
SIGNATURE:	/Denise Cooper/
DATE SIGNED:	02/02/2017
Total Attachments: 4	
source=WW Assignments-INV-AZUK#page1.tif	

source=WW Assignments-INV-AZUK#page2.tif

source=WW Assignments-INV-AZUK#page3.tif

source=WW Assignments-INV-AZUK#page4.tif

THIS CONFIRMATORY ASSIGNMENT is made the 30th day of May 2015 (the “Effective Date”)

BY AND BETWEEN

Maurice Raymond Verschoyle FINLAY and Jon James WINTER-HOLT both British citizens and Johannes Wilhelmus Maria NISSINK a Dutch citizen all of AstraZeneca R&D Cambridge, Darwin Building, Cambridge Science Park, Milton Road, Cambridge, England, CB4 0FZ and Piotr Antoni RAUBO a Polish citizen of AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire, England, SK10 4TG (the “Inventor(s)”)

AND

ASTRAZENECA UK LIMITED, a company incorporated in England and Wales under No. 3674842 with registered office address at 2 Kingdom Street, London, England W2 6BD (“AstraZeneca”)

Recitals

WHEREAS

- A. The Inventor(s) have made certain inventions (the “Inventions”) in respect of which the patent application(s) specified in the attached Schedule have been filed (the “Patent Application(s)”).
- B. The Inventor(s) were at all relevant times an employee of AstraZeneca.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. In consideration of the amounts paid to the Inventor(s) pursuant to their contract of employment with AstraZeneca, the Inventor(s) hereby confirm(s) that by virtue of their employment with AstraZeneca they have assigned, and in so far as there may be any outstanding Rights that have not been assigned to AstraZeneca do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to AstraZeneca absolutely all their right, title and interest in and to the Inventions, the Patent Application(s) and any Patents; any divisions, continuations and continuations-in-part of the Patent Application(s); any re-issues, re-examinations, or extensions of any and all Patents; the right to file patent applications directly in the name of AstraZeneca or an affiliated company of AstraZeneca (in countries or regions where filings are permissible); and the right to claim priority rights deriving from the Patent Application(s) (collectively, the “Rights”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Inventor(s) warrant(s) that the Rights are unencumbered. The Inventor(s) acknowledge(s) that AstraZeneca shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and the Inventor(s) waive(s) any right of first refusal that they may have for acquiring such Rights. The Inventor(s) further acknowledge(s) that insofar as and solely to the extent that the Rights apply to India, the amount paid to the Inventor(s) pursuant to their contract of employment includes nominal consideration of One GBP (£1.00).
2. The Inventor(s) each hereby agree(s) with AstraZeneca that their assignment to AstraZeneca includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Patent Application(s), including all rights to recover damages, profits and injunctive relief for infringement of any of the Patent Application(s).
3. The Inventor(s) each hereby agree(s) with AstraZeneca that they will execute such further documents and give such assistance at the expense of AstraZeneca as AstraZeneca may require:
 - a) to secure the vesting in AstraZeneca of all rights in the Patent Application(s) and in such parties to whom AstraZeneca may assign its rights in the Patent Applications;
 - b) to defeat any challenge to the validity of and resolve any questions concerning the Patent Application(s); and
 - c) to apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Patent Application(s), including the right to claim convention priority from such applications and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.

4. The Inventor(s), on behalf of itself and its successors, assigns, nominees, or other legal representatives, does hereby covenant and agree with AstraZeneca that they shall, at the expense of AstraZeneca, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by AstraZeneca to enable AstraZeneca or its successors, nominees or assigns to enjoy the full benefit of the rights assigned by this agreement.

5. The Inventor(s) on behalf of itself and its successors, assigns, nominees, or other legal representatives, do hereby authorize AstraZeneca, its successors, assigns, or nominees, including its patent agents, to amend the present assignment document to insert or correct the filing date, serial number or other identifying information of the Patent Application(s) and/or Patents as may be needed to record same.

6. AstraZeneca accepts the above assignment.

7. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

This agreement has been entered into on the Effective Date.


Signed at: Cheshire, England


Date: 17th June 2015


Piotr Antoni RAUBO

Witnessed by:

Witnessed by:


Name: 


Name:  K. EVANS

Signed at: Cambridge, England

Date: 18th June 2015



Jon James WINTER-HOLT



Johannes Wilhelmus Maria NISSINK


Maurice Raymond Verschoyle FINLAY

Witnessed by:

Witnessed by:

Name:  ATTILLA TING

Name:  IAIN SIMPSON

Signed at: Cheshire, England

Date: 17th June 2015




Signed for and on behalf of
ASTRAZENECA UK LIMITED

Name: Lucy PADGET

Capacity: Authorised Signatory

Witnessed by:



Name: Jennifer Pennington

THE SCHEDULE

THE PATENT APPLICATION(S)					
AstraZeneca Case No:	Application Ref:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
200230-AR-NP	A	Argentina	National	20150101720	29th May 2015
200230-BO-NP	B	Bolivia	National	SP 00103-2015	29th May 2015
200230-ET-NP	C	Ethiopia	National	1, 3, 4-Thiadiazole Compounds and Their Use in Treating Cancer	To be advised
200230-WO-PCT	D	International	PCT	PCT/GB2015/051537	27th May 2015
200230-LB-NP	E	Lebanon	National	10663	29th May 2015
200230-PY-NP	F	Paraguay	National	23439/2015	29th May 2015
200230-PK-NP	G	Pakistan	National	1, 3, 4-Thiadiazole Compounds and Their Use in Treating Cancer	To be advised
200230-TW-NP	H	Taiwan	National	1, 3, 4-Thiadiazole Compounds and Their Use in Treating Cancer	29th May 2015
200230-UY-NP	I	Uruguay	National	36.145	28th May 2015
200230-VE-NP	J	Venezuela	National	1, 3, 4-Thiadiazole Compounds and Their Use in Treating Cancer	To be advised
200230-BS-NP	K*	Bahamas	National	1, 3, 4-Thiadiazole Compounds and Their Use in Treating Cancer	To be advised
200230-JM-NP	L*	Jamaica	National	18/1/5675	18th May 2015

Patent Application(s) referenced A to J inclusive claim priority from the following GB Application(s)

Application No.	Filing Date
1409624.2	30th May 2014

Patent Application(s) referenced K* and L* do not claim priority